Evidence for risk stratification when monitoring for toxicities following initiation of combination antiretroviral therapy

Babafemi Taiwo, Elizabeth L. Yanik, Sonia Napravnik, Patrick Ryscavage, Susan L. Koletar, Richard Moore, W. Christopher Mathews, Heidi M. Crane, Kenneth Mayer, Anne Zinski, James S. Kahn, Joseph J. Eron

Research output: Contribution to journalArticlepeer-review

4 Scopus citations


Objective: Laboratory monitoring is recommended during combination antiretroviral therapy (cART), but the pattern of detected abnormalities and optimal monitoring are unknown. We assessed laboratory abnormalities during initial cART in 2000-2010 across the United States. Design: Observational study in the Centers for AIDS Research Network of Integrated Clinical Systems Cohort. Methods: Among patients with normal results within a year prior to cART initiation, time to first significant abnormality was assessed by Kaplan-Meier curves stratified by event type, with censoring at first of regimen change, loss to follow-up, or 104 weeks. Incidence rates of first events were estimated using Poisson regression; multivariable analyses identified associated factors. Results were stratified by time (16 weeks) from therapy initiation. Results: A total of 3470 individuals contributed 3639 person-years. Median age, pre-cART CD4, and follow-up duration were 40 years, 206 cells/μl, and 51 weeks, respectively. Incidence rates for significant abnormalities (per 100 person-years) in the first 16 weeks post-cART initiation were as follows: lipid = 49 [95% confidence interval (CI) 41 - 58]; hematologic = 44 (40-49); hepatic = 24 (20-27); and renal = 9 (7-11), dropping substantially during weeks 17-104 of cART to lipid = 23 (18-29); hematologic = 5 (4-6); hepatic = 6 (5-8); and renal = 2 (1-3) (all P<0.05). Among patients receiving initial cART with no prior abnormality (N= 1889), strongest associations for hepatic abnormalities after 16 weeks were hepatitis B and C [hazard ratio = 2.3 (95% CI 1.2-4.5) and hazard ratio=3.0 (1.9-4.5), respectively]. The strongest association for renal abnormalities was hypertension [hazard ratio = 2.8 (1.4-5.6)]. Conclusion: New abnormalities decreased after week 16 of cART. For abnormalities not present by week 16, subsequent monitoring should be guided by comorbidities.

Original languageEnglish (US)
Pages (from-to)1593-1602
Number of pages10
Issue number10
StatePublished - Jun 19 2013

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Infectious Diseases


Dive into the research topics of 'Evidence for risk stratification when monitoring for toxicities following initiation of combination antiretroviral therapy'. Together they form a unique fingerprint.

Cite this